InnoVet Inc. announced that it has submitted a product licenseapplication (PLA) to the U.S. Department of Agriculture forapproval to market its IVET 629 immune stimulant for treatingchronic respiratory disease in horses.

About 30 percent of the horses in the U.S. -- or 2 million --experience one or more episodes of respiratory disease eachyear. That market, according to Jesse Houdeshell, InnoVet'spresident, is currently served by two products. But InnoVet'sIVET 629, trade-named Stimugen, requires from one to twodoses per episode, while the others require from three to fivedoses. This potentially gives Stimugen a good chance ofgrabbing a respectable share of the market.

Stimugen stimulates B lymphocytes. InnoVet (NASDAQ:IVET) ofWest Palm Beach, Fla., is also testing it in dogs and cats fortreating lymphomas and mammary tumors, and has a modifiedversion it is about to test in humans with lymphoma. "Studiesin human volunteers should start in about six weeks,"Houdeshell told BioWorld.

(c) 1997 American Health Consultants. All rights reserved.